UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $95.03 and traded as high as $95.64. UCB shares last traded at $94.71, with a volume of 5,059 shares.
UCB Price Performance
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The stock has a fifty day simple moving average of $95.03 and a two-hundred day simple moving average of $86.43.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Earnings Per Share Calculator: How to Calculate EPS
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Want to Profit on the Downtrend? Downtrends, Explained.
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
